Hyperion Therapeutics To Report Fourth Quarter And Full Year 2013 Financial Results After Market On February 27, 2014

BRISBANE, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report fourth quarter and full year 2013 financial results after market closes on Thursday, February 27, 2014. Hyperion will host a webcast and conference call with management to discuss financial results, as well as provide a general corporate update, at 4:30 p.m. ET (1:30 p.m. PT).

A live audio webcast of the conference call can be accessed on Hyperion's investor relations website at: http://investors.hyperiontx.com/events.cfm

To access the live conference call, dial 877-847-7188 U.S. or 408-427-3787 International and use the conference ID# 69490013. A replay of the call will be available for seven days by accessing Hyperion's investor relations website or by dialing 855-859-2056 U.S. or (404) 537-3406 International and use conference ID# 69490013 beginning approximately one hour after the conference call concludes.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. For more information, please visit www.hyperiontx.com .
CONTACT: Sylvia Wheeler, Investor Relations         (650) 794-7834

If you liked this article you might like

Ireland’s Horizon Pharma Makes $3 Billion Hostile Bid for Depomed

Ireland’s Horizon Pharma Makes $3 Billion Hostile Bid for Depomed

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Stock Markets Soar on Trifecta of Good News

Stock Markets Soar on Trifecta of Good News

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion